Are the inotropic and antiarrhythmic effects of bradykinin due to increases in coronary flow?

American Journal of Cardiology

Volumn 80, Issue 3 A, 1997, Pages 148A-152A

  Minshall, Richard D ^a   Vogel, Stephen M ^a   Rabito, Sara F ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; BRADYKININ; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INOTROPIC AGENT; RAMIPRILAT;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; CONFERENCE PAPER; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DILATATION; DRUG MECHANISM; ELECTROCARDIOGRAM; ENZYME SUBSTRATE; HEART ARRHYTHMIA; HEART MUSCLE CONTRACTILE FORCE; INOTROPISM; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; VASODILATATION;

EID: 0030810495     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(97)00471-2     Document Type: Conference Paper

References (21)

1. Linz W, Schölkens BA, Han YF. Beneficial effects of the converting enzyme inhibitor, ramipril, in ischemic rat hearts. J Cardiovasc Pharmacol. 8:1986;S91-S99.
2. van Gilst WH, de Graeff PA, Wesseling H, de Langen CDJ. Reduction of reperfusion arrhythmias in the ischemic isolated rat heart by angiotensin-converting enzyme inhibitors: a comparison of captopril, enalapril, and Hoe 498. J Cardiovasc Pharmacol. 8:1986;722-728.
3. Liu Y-H, Yang X-P, Sharov VG, Sigmon DH, Sabbah HN, Carretero OA. Paracrine systems in the cardioprotective effect of angiotensin-converting enzyme inhibitors on myocardial ischemia/reperfusion injury in rats. Hypertension. 27:1996;7-13.
4. Shimada Y, Avkiran M. Attenuation of reperfusion arrhythmias by selective inhibition of angiotensin-converting enzyme/kininase II in the ischemic zone: mediated by endogenous bradykinin? J Cardiovasc Pharmacol. 27:1996;428-438.
5. Gohlke P, Linz W, Schölkens BA, Kuwer I, Bartenbach S, Schnell A, Unger T. Angiotensin-converting enzyme inhibition improves cardiac function. Role of bradykinin. Hypertension. 23:1994;411-418.
6. Massoudy P, Becker BF, Gerlach E. Bradykinin accounts for improved postischemic function and decreased glutathione release of guinea pig heart treated with the angiotensin-converting enzyme inhibitor ramiprilat. J Cardiovasc Pharmacol. 23:1994;632-639.
7. Noda K, Sasaguri M, Ideishi M, Ikeda M, Arakawa K. Role of locally formed angiotensin II and bradykinin in the reduction of myocardial infarct size in dogs. Cardiovasc Res. 27:1993;334-340.
8. McDonald KM, Mock J, D'Aloia A, Parrish T, Hauer K, Francis G, Stillman A, Cohn JN. Bradykinin antagonism inhibits the antigrowth effect of converting enzyme inhibition in the dog myocardium after discrete transmural myocardial necrosis. Circulation. 91:1995;2043-2048.
9. Erdös EG, Sloane EM. An enzyme in human blood plasma that inactivates bradykinin and kallidins. Biochem Pharmacol. 11:1962;585-592.
10. Erdös EG. Angiotensin I converting enzyme and the changes in our concepts through the years. Hypertension. 16:1990;363-370.
11. Walker MJA, Curtis MJ, Hearse DJ, Campbell RWF, Janse MJ, Yellon DM, Cobbe SM, Coker SJ, Harness JB, Harron DWG, Higgins AJ, Julian DG, Lab MJ, Manning AS, Northover BJ, Parratt JR, Riemersma RA, Riva E, Russell DC, Sheridan DJ, Winslow E, Woodward B. The Lambeth Conventions: guidelines for the study of arrhythmias in ischemia, infarction, and reperfusion. Cardiovasc Res. 22:1988;447-455.
12. Kimura E, Hashimoto K, Furukawa S, Hayakawa H. Changes in bradykinin level in coronary sinus blood after the experimental occlusion of a coronary artery. Am Heart J. 85:1973;635-647.
13. Matsuki T, Shoji T, Yoshida S, Kudoh Y, Motoe M, Inoue M, Nakata S, Hosoda S, Shimamoto K, Yellon D, Iimura O. Sympathetically induced myocardial ischaemia causes the heart to release plasma kinin. Cardiovasc Res. 21:1987;428-432.
14. Baumgarten CR, Linz W, Kunkel G, Schölkens BA, Wiemer G. Ramiprilat increases bradykinin outflow from isolated hearts of rat. Br J Pharmacol. 108:1993;293-295.
15. Munch PA, Longhurst JC. Bradykinin increases myocardial contractility: relation to the Gregg phenomenon. Am J Physiol. 260:1991;R1095-R1103.
16. Fort S, Lewis MJ. A factor released from coronary vascular endothelium inhibits myocardial contractile performance. Am J Physiol. 246:1993;H830-H836.
17. Feletou M, Vanhoutte PM. Endothelium-dependent hyperpolarization of canine coronary smooth muscle. Br J Pharmacol. 93:1988;515-524.
18. Campbell WB, Gebremehhin D, Pratt PF, Harder DR. Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circ Res. 78:1996;415-423.
19. Minshall DR, Yelamanchi VP, Djokovic A, Miletich DJ, Erdös EG, Rabito SF, Vogel SM. Importance of the sympathetic innervation in the positive inotropic effects of bradykinin and ramiprilat. Circ Res. 74:1994;441-447.
20. 2 mediates the stimulation of inositol 1,4,5-trisphosphate production and intracellular calcium mobilization by bradykinin in neonatal rat ventricular cardiomyocytes. Hypertension. 28:1996;444-449.
21. 2 receptors in adult myocardium and neonatal rat cardiomyocytes. Circ Res. 76:1996;773-780.